Pyxis Oncology Reports Positive MICVO Phase 1 Data In 2L+ Head And Neck Cancer

Pyxis Oncology reported positive updated data from an ongoing Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in patients with second-line and later recurrent/metastatic head and neck squamous cell carcinoma. The early-stage clinical update is a positive catalyst for PYXS, though the article provides no efficacy, safety, or patient-enrollment figures to quantify the result.